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BACKGROUND: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death globally. Mechanistic
target of rapamycin (mTOR) is frequently up-regulated in HCC and plays an important role in HCC tumorigenesis.
Tumors with loss of tuberous sclerosis complex 2 (TSC2), a negative regulator of mTOR signaling, tend to respond
well to mTOR inhibitors. We analyzed TSC2 expression status in Korean patients with HCC and evaluated the
correlation between TSC2 loss and response to the mTOR inhibitor, everolimus. METHODS: We retrospectively
assessed 36 patients with advanced HCC who had received sorafenib at a single center in Korea between 2008
and 2014, and for whom tumor specimens were available for TSC2 immunohistochemical analysis (IHC). Three
patient-derived tumor cell lines (PDCs) were analyzed by western blotting to determine TSC2 expression and drug
sensitivity to mTOR. RESULTS: Twelve of 36 patients (33.3%) showed low to undetectable levels of TSC2
expression. No significant differences were observed in progression-free survival (PFS) or overall survival with
sorafenib treatment based on TSC2 expression status. Two patients were treated with everolimus after sorafenib
failure; one patient, with moderate TSC2 expression, experienced stable disease with a PFS of 5.8 months; the
other, with high TSC2 expression, experienced rapid progression. PDC models demonstrated that the TSC2-low
HCC PDC line was significantly more sensitive to everolimus than the TSC2-high HCC PDC lines. CONCLUSION:
Loss of TSC2 may predict improved response to everolimus in HCC patients, but further studies are needed to
confirm the predictive role of TSC2 expression for everolimus treatment.
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Hepatocellular carcinoma (HCC) is the fifth most common
malignancy and the second leading cause of cancer-related deaths in
the world [1]. The majority of patients diagnosed with HCC have
advanced disease, and many are not eligible for potentially curative
therapies, such as surgical therapies and loco-regional procedures [2].
Previous studies evaluating cytotoxic chemotherapy for the treatment
of patients with advanced HCC failed to demonstrate a significant
improvement in overall survival [3]. Recently, sorafenib, an oral
multi-targeted tyrosine kinase inhibitor, has been shown to produce a
significant improvement in overall survival in two phase III trials for
the treatment of patients with HCC, establishing sorafenib as the only
standard systemic treatment in advanced HCC [4,5]. However, the
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remains an unmet need for more effective novel therapies to improve
the poor survival outcomes of treatment for advanced HCC.
The mammalian target of rapamycin (mTOR), which is regulated
by the PI3K/Akt signaling pathway, is a key regulator of growth and
proliferation of tumor cells [6]. Up-regulation of mTOR signaling has
been reported in approximately 40% to 60% of patients with HCC,
and is associated with early recurrence and poor prognosis [7,8].
Everolimus, a rapamycin analog, inhibits the mTOR pathway and
blocks tumor growth in xenograft models of human HCC [8].
However, treatment with everolimus in advanced HCC patients for
whom sorafenib failed has shown no significant improvement in
overall survival in a large, randomized, placebo-controlled phase III
clinical trial (EVOLVE-1) [9].
An important inhibitor of mTOR activity is the tuberous sclerosis
complex (TSC), which is composed of TSC1 and TSC2 [10].
Growth factor regulation of mTOR occurs largely through regulation
of the GTPase activating protein (GAP) activity of the TSC1/TSC2
protein complex for the Ras family member Rheb [11]. Phosphor-
ylation of TSC2 by Akt, or other kinases that inactivate TSC2,
activates its downstream target Rheb, which stimulates phosphory-
lation and activation of the mTOR complex [12]. Everolimus is an
effective treatment for TSC manifestations, a rare disease associated
with mutations in TSC1 and TSC2 that result in high mTOR activity
[13]. A recent retrospective study reported that patients with loss of
TSC2 tended to respond better to everolimus, which suggests that
TSC2 status could predict a selective response to everolimus [14].
Based on these findings, we aimed to analyze TSC2 expression
status in Korean patients with advanced HCC and to evaluate the
correlation between TSC2 expression status and the response of the
mTOR inhibitor, everolimus. Furthermore, we examined the
antitumor activity of everolimus based on TSC2 expression status
through patient-derived tumor cell (PDC) models.
Material and Methods
Patient Selection
We collected and reviewed the medical records of 36 patients with
advanced or metastatic HCC who were treated with sorafenib
between 2008 and 2014 at a single center in Korea. Patients
with histologically diagnosed HCC, whose tumor specimens were
available for immunohistochemical (IHC) staining of TSC2
expression were eligible for the study. Clinical information including
age, sex, etiology, Eastern Cooperative Oncology Group (ECOG)
performance status, Barcelona Clinic Liver Cancer (BCLC) staging
system, Child-Pugh class, macroscopic vascular invasion, extrahepatic
spread, alpha-fetoprotein (AFP), and previous treatment were
extracted from hospital records. This study was approved by the
institutional review board of the Samsung Medical Center.
TSC2 Immunohistochemical Analysis
Formalin-fixed paraffin-embedded tissue including both HCC and
adjacent non-tumorous liver were sectioned with 4 μm thickness. IHC
study was performed using Bond-Max auto-immunostainer (Leica
Biosyatem, Melbourne, Australia). Antigen retrieval was performed
with ERI buffer at pH 6.0 for 20 minutes. The sections were incubated
with rabbit monoclonal antibody to TSC2 (#4308, 1:200; Cell
Signaling technology) for 15 minutes at 37 °C. Bond Polymer Refine
Detection kit (Leica) was used for chromogenic reaction. Noimmunoreactivity was observed in tissue sections used as negative
control in which primary antibody was replaced by isotype-matched
irrelevant antibody. Positive control (human normal kidney) showed
cytoplasmic TSC2 expression in epithelial cells of convoluted tubules.
IHC staining was assessed by a pathologist (C.K. Park) without
knowledge of the patients' characteristics. The sections were scored by
combining the proportion and intensity of the stained cells as reported
previously [14]. The proportion of stained tumor cells was determined
semiquantitatively and the staining intensity was classified as 0
(negative), 1 (weak), 2 (moderate), and 3 (strong). The histo-score
(H-score) of each tumor was calculated by multiplication of the
proportion of stained cells and the staining intensity [14].
Cell Culture
HCC cells were obtained from pericardial effusions and ascites
drained for therapeutic purposes after obtaining written informed
consent. The protocol was approved by the Institutional Review
Board (IRB) at the Samsung Medical Center. The cells were cultured
in RPMI 1640 medium (Gibco, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (FBS).
Cell Viability Assay
After pathologic confirmation, cells were seeded at 5 × 103 cells on
96-well plates and incubated for 24 hours at 37°C. Cells were then
treated with different doses of everolimus (3-fold serial dilutions
starting at 10 μM/ml) and incubated for 5 days at 37°C. Cell growth
inhibition was determined using a CellTiter-Glo Luminescent Cell
Viability assay (Promega, Madison, WI, USA) according to the
manufacturer's protocol. The absorbance value of each well was
measured with a microplate reader set at 490 nm. All experiments
were performed in triplicate.
Western Blot Analyses
HCC cells were cultured in RPMI 1640 medium with 10% FBS at
37°C. Cells were seeded at a concentration of 1 × 106 cells per
100-mm dish and incubated at 37°C for 24 hours. Cells were then
incubated with the drug (1 μM everolimus) in RPMI 1640 medium
with 10% FBS at 37°C for an additional 3 days. Total cells were lysed
in lysis buffer containing 20 mM HEPES (pH 7.4), 150 mM NaCl,
1 mM MgCl2, 1 mM EDTA, 2 mM EGTA, 10% glycerol, 1%
Triton X-100, 1 μg/ml of leupeptin, and 1 μg/ml of aprotinin. Equal
amounts (30 μg) of cell lysates were dissolved in 8% Bis-Tris gels with
MOPS running buffer (Invitrogen, Carlsbad, CA, USA), transferred
onto a nitrocellulose membrane and incubated overnight at 4 °C with
the following primary specific antibodies: rabbit anti-human
Tuberin/TSC2 (D93F12) Ab (1:1000 dilution), rabbit anti-human
phosphorylated mTOR (Ser2448) Ab (1:700 dilution), rabbit
anti-human mTOR Ab (1:700 dilution) from Cell Signaling
Technologies (Beverly, MA, USA), and b-tubulin (1:5000 dilution)
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Membranes
were incubated with HRP-conjugated anti-rabbit or anti-mouse
secondary antibodies (1:3000 dilution) for 3 hours and bands were
visualized using the ECL Western Blotting Detection System (GE
Healthcare, Buckinghamshire, UK).
Statistical Analysis
Progression-free survival (PFS) and overall survival was calculated
using the Kaplan-Meier method and compared using the log-rank
test. P b .05 was considered statistically significant.
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TSC2 IHC Expression Status and Survival Outcomes
We retrospectively assessed 36 patients with advanced HCC who
had tumor specimens available for TSC2 immunohistochemical
analysis. Most patients did not have macroscopic vascular invasion
(75%), and had Barcelona Clinic Liver Cancer stage C disease
(94.4%). The most common etiology of HCC was hepatitis B virus
(HBV) and the disease was rated as Child-Pugh class A in 34 (94.4%)
patients. All patients had received sorafenib and the median PFS of
sorafenib treatment was 2.5 months. Tumor specimens for TSC2
IHC analysis were obtained from liver (66.7%), lung (19.4%) and
other metastatic sites (13.9%). The median time interval between
acquisition of histologic specimen for TSC2 IHC analysis and starting
sorafenib treatment was 11.7 months. Immunoreactivity for TSC2
was observed in the cytoplasm of tumor cells. Of the 36 patients, two
had minimal TSC2 IHC expression (TSC2 H-score = 0-60), 10 had
low TSC2 IHC expression (TSC2 H-score = 61-120), 11 had
moderate TSC2 IHC expression (TSC2 H-score = 121-180), and
13 had high TSC2 IHC expression (TSC2 H-score = 181-300)
(Figure 1, A and B). Based on previous research, in which TSC2
immunostaining scores from 0 to 120 were defined as TSC2 null/low
[14], 12 (33.3%) patients were considered TSC2 null/low. ThereFigure 1. TSC2 IHC histo-score (H-score) range distribution in 36 hepa
hepatocellular carcinoma. (A) H-scores were divided into four groups:
300 (high). The percentage of each range is marked at the top of th
expression (B) and high cytoplasmic expression (C) in hepatocellularwere no significant differences in median PFS or overall survival (OS)
with sorafenib treatment between TSC2 null/low patients and the
others (2.5 months vs. 2.0 months, P = .054; 15.5 months vs. 14.1
months, P = .348, respectively). Patients' baseline characteristics and
survival outcomes following sorafenib treatment are described in
Table 1.
Two (5.6%) patients received everolimus after sorafenib failure.
The TSC2-high patient (TSC2 H-score = 230) experienced a shorter
PFS of 2.1 months compared with the TSC2-moderate patient
(TSC2 H-score = 150), whose PFS was 5.8 months (Table 2).
Figure 2 illustrates the computed tomography (CT) scan images at
baseline and following two cycles of everolimus treatment for these
two patients. The TSC2-moderate HCC patient with lung and brain
metastasis experience stable disease after two cycles of everolimus
treatment, whereas the TSC2-high HCC patient with lung metastasis
experienced rapid progression of the lung metastasis.
TSC2 Loss and Efficacy of Everolimus in PDC Models
We had previously established three PDCs for testing the
antitumor activity of various agents. In order to examine the effect
of loss of TSC2 on the antitumor effect of everolimus, we performed
western blot analyses of TSC2, mTOR, and phosphorylation of
mTOR (p-mTOR). As shown in Figure 3A, one PDC (YSY) showedtocellular carcinomas and two examples of IHC staining for TSC2 in
0 to 60 (minimal), 61 to 120 (low), 121 to 180 (moderate), and 181 to
e bars. (B and C) Immunostaining of TSC2 show low cytoplasmic
carcinoma (×200).
Table 1. Patients Baseline Characteristics and Survival Outcomes of Sorafenib Treatment Based on
TSC2 IHC Status
Variables TSC2-Null/
Low* (N = 12)
TSC2-Moderate/
High (N = 24)
Total
(N = 36)
Median age, years (range) 61 (43-75) 57 (35-85) 57 (35-85)
Gender, n (%)
Male 9 (75.0) 34 (100.0) 33 (91.7)
Female 3 (25.0) 0 (0) 3 (8.3)
Cause of disease, n (%)
Hepatitis B 10 (83.3) 18 (75.0) 28 (77.8)
Hepatitis C 0 1 (4.2) 1 (2.8)
Unknown 2 (16.7) 5 (20.8) 7 (19.4)
ECOG performance status, n (%)
0 7 (58.3) 15 (62.5) 22 (61.1)
1 5 (41.7) 9 (37.5) 14 (38.9)
BCLC stage
B (intermediate) 0 2 (8.3) 2 (5.6)
C (advanced) 12 (100.0) 22 (91.7) 34 (94.4)
Macroscopic vascular invasion, n (%) 3 (25.0) 6 (25.0) 9 (25.0)
Extrahepatic spread, n (%) 11 (91.7) 21 (87.5) 32 (88.9)
Lung 9 (75.0) 13 (79.2) 22 (61.1)
Lymph node 1 (8.3) 5 (20.8) 6 (16.7)
Child-Pugh class
A 11 (91.7) 23 (95.8) 34 (94.4)
B 1 (8.3) 1 (4.2) 2 (5.6)
AFP ≥ 200 ng/mL, n (%) 5 (41.7) 6 (25.0) 11 (30.6)
Previous therapy
Liver resection 9 (75.0) 22 (91.7) 31 (86.1)
Locoregional therapy
Transarterial chemoembolization 7 (58.3) 21 (87.5) 28 (77.8)
Radiofrequency ablation 4 (33.3) 12 (50.0) 16 (44.4)
Radiotherapy 10 (83.3) 8 (33.3) 18 (50)
Metasectomy 5 (41.7) 8 (33.3) 13 (36.1)
Systemic chemotherapy 3 (25.0) 2 (8.3) 5 (13.9)
Site of tumor specimen acquisition
Liver 8 (66.7) 16 (66.7) 24 (66.7)
Lung 2 (16.7) 5 (20.8) 7 (19.4)
Other metastatic lesion 2 (16.7) 3 (12.5) 5 (13.9)
Interval from specimen acquisition to
starting sorafenib treatment, months
8.6 11.7 11.7
Progression free survival, months 2.5 2.0 2.5
Overall survival, months 15.5 14.1 14.1
ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer; AFP,
alpha-fetoprotein.
* TSC2 IHC scores ranging from 0 to 120 were defined as TSC2 null/low.
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decreased levels of mTOR and p-mTOR after treatment with
everolimus. In contrast, the other two PDCs (KKS and KHK) with
wild-type TSC showed insignificant changes in mTOR and p-mTOR
after the same treatment with everolimus.
The half maximal inhibitory concentration (IC50) is a measure of
the effectiveness of a substance in inhibiting a specific biological or
biochemical function. As shown in Figure 3, B and C, everolimus
exhibited promising antitumor activity in the TSC2-low PDC (YSY),
with an IC50 value of 1.5 μM/ml compared with the two TSC2-wild
PDCs (KKS and KHK), which showed IC50 values above 10 μM/ml.Table 2. Patients Profile and Survival Outcomes of Two HCC Patients with Everolimus Treatment
Based on TSC2 IHC Expression
Patient
ID
Sex Age TSC
IHC
Best
Response
PFS
(months)
Previous
Sorafenib Failure
Presence of
Hepatitis Virus
Site of
Metastasis
1 M 63 150 Stable
disease
5.8 Yes HBV Carrier Lung,
brain
2 M 50 230 Progression 2.1 Yes HBV Carrier LungDiscussion
HCC is highly resistant to chemotherapeutic agents, and few
treatment options are available for advanced disease. Although
large-scale randomized clinical trials have proven that sorafenib
improves the probability of survival in patients with advanced HCC
[4,5], no other targeted agents have demonstrated survival benefits
against HCC. The PI3K/Akt/mTOR pathway plays a critical role in
carcinogenesis [15] and mTOR is an important mediator of the
PI3K-Akt pathway, which acts as a central regulator of cell growth
and proliferation and progression from G1 to S phase. Despite the
high frequency of mTOR activation in HCC, the EVOLVE-1 clinical
trial to assess the efficacy of the mTOR inhibitor everolimus found no
associated improvement in overall survival [9]. Thus, predictive
markers are needed to maximize the efficacy of everolimus in a clinical
setting. Hyunh et al. [14] suggested that loss of TSC2 could predict a
selective response to everolimus. In that study, which defined TSC2
H-scores of 60 and 120 as the cutoff values for TSC2-null and
TSC2-low tumors, respectively, the frequency of TSC2-null or -low
IHC expression was higher in Asian patients than in Caucasian
patients, up to approximately 40% of 239 patients. Similarly, the
frequency of TSC2-null or -low IHC expression in our study was
33.3% of 36 HCC patients. No significant difference between TSC2
expression status and survival outcome was observed with sorafenib
treatment, and patients with high TSC2 IHC expression seemed to
show a poor response to everolimus.
Tumor heterogeneity can make treatment responses difficult to
predict but understanding the molecular basis of tumorigenesis can
help to identify treatment targets. TSC1 and TSC2 were identified in
1997 and 1993, respectively, as the genetic loci mutated in the
autosomal dominant tumor syndrome TSC [16,17]. TSC1 and
TSC2 act as tumor suppressors in various cancers [18,19], and several
studies have suggested that inactivating mutations in TSC1/2 might
be a potent predictive biomarker of potential response to mTOR
inhibitors [14,20–22]. Hyunh et al. reported that the loss of TSC2, as
determined by immunoblot analysis, was associated with increased
mTOR activity and decreased Akt phosphorylation [14]. Further-
more, TSC2-null cell lines showed enhanced sensitivity, with greater
inhibition of cell proliferation to everolimus than TSC2-wild type cell
lines in a patient-derived HCC xenograft study, consistent with the
results of our PDC study. PDCs are in vitro cell models generated
from freshly resected patient tumors or malignant body fluids that
preserve the histologic and genomic features of primary tumor cells
[23]. PDC models have been suggested to be promising models for
preclinical experiments and to closely resemble the patient tumor
genome and clinical response. In our study, everolimus exhibited
potent antitumor activity in TSC2-low PDCs compared with
TSC2-wild type PDCs.
Because inactivating mutations in TSC1/TSC2 have been
identified at low frequency in various common forms of cancer
through The Cancer Genome Atlas (TCGA) program [24] and
because sequencing to identify mutations cannot always predict
protein loss, IHC analysis is a useful approach for identifying the
functional status of TSC2. Non-genetic mechanisms of TSC2 loss
may result in a relatively higher frequency of TSC2 null/low IHC
expression compared with TSC1/2 inactivating mutations. Promoter
methylation, phosphorylation, and acetylation might be responsible
for silencing of TSC2[25]. TSC2 null or low expression is common in
Asian HCC patients, with a frequency of approximately one third.
These findings suggest that TSC2 loss might be a potential predictive
Figure 2. Comparisonof responsewith everolimus treatment basedonTSC2 IHCexpression. (A andB) Twocomputed tomography (CT) scan
images of a HCCpatient with lung and brainmetastasiswhose tumor expressedmoderate TSC2 IHC staining (patient ID 1) at baseline (A) and
following two cycles of everolimus treatment (B). (C and D) Two computed tomography (CT) scan images of a HCC patient with lung
metastasiswhose tumor expressed high TSC2 IHC staining (patient ID 2) at baseline (C) and following two cycles of everolimus treatment (D).
Figure 3. TSC2 loss in patient-derived HCC cell could predict everolimus efficacy. (A) Western blot analysis of three HCC cell lines with indicated
antibodies. YSY cell line, expressed low TSC2 protein level, showed decreasing the phosphorylation ofmTOR by everolimus. (B) Drug sensitivity to
everolimus. IC50 valuesof KKS, KHK, andYSYcellwereN10,N10, and1.5μM, respectively. (C)Graphsof everolimus IC50 valuesof threeHCCcells.
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with HCC. However, lack of a clear cutoff value for TSC2 loss limits
the validation of TSC2 expression as a predictor of mTOR inhibitors.
Standardization of immunostaining and scoring methods for TSC2
expression should be established to improve the utility of TSC2
expression as a predictive biomarker.
In conclusion, although this study has some limitations, such as the
retrospective nature of the analysis and the small number of patients,
the mTOR inhibitor everolimus exhibited promising antitumor
activity in TSC2 null/low HCC patients. Further large prospective
studies are needed to identify whether TSC2 loss can serve as a
predictive marker for everolimus treatment.
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